Breaking News, Collaborations & Alliances

Sanofi Licenses AI-Discovered Biologics from Earendil Labs

Aims to accelerate the development of HXN-1002 and HXN-1003.

Author Image

By: Charlie Sternberg

Associate Editor

Image by md saidul Islam from Pixabay.

Earendil Labs, an expert in AI-driven research and development of next-generation biologics therapeutics, and Sanofi have entered into a license agreement for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases. Under the agreement, Sanofi will obtain exclusive worldwide rights to two bispecific antibodies, HXN-1002 and HXN-1003, both utilizing Earendil Labs’ proprietary AI and high-throughput discovery & research platform. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics